This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mericq, M. V. Articles by Cassorla, F. Search for Related Content PubMed PubMed Citation Articles by Mericq, M. V. Articles by Cassorla, F.

Near Final Height in Pubertal Growth Hormone (GH)-Deficient Patients Treated with GH Alone or in Combination with Luteinizing Hormone-Releasing Hormone Analog: Results of a Prospective, Randomized Trial¹

Institute of Maternal and Child Research (M.V.M., M.E., A.A., F.C.), University of Chile, Santiago, Chile; and DEB, NICHD (G.B.C.), National Institutes of Health, Bethesda, Maryland 20892

Address correspondence and requests for reprints to: M. Verónica Mericq, IDIMI, University of Chile, Casilla 226-3, Santiago, Chile.

To study the effects of delaying puberty in GH-deficient (GHD) children, we studied 21 GHD (9 boys, 14 girls), treatment-naive, pubertal patients in a prospective, randomized trial. Their chronological age was 14.3 ± 1.6 yr, and their bone age was 11.3 ± 1.1 yr (mean ± SD) at the beginning of the study. Four patients who developed hypogonadotropic hypogonadism were subsequently excluded from the study. Patients were randomly assigned to receive GH + LH-releasing hormone analog (LHRH-A) (n = 7), or GH alone (n = 10). GH and LHRH-A treatment started simultaneously in each patient. GH (Nutropin) was administered at a dose of 0.1U/kg·day sc, until patients reached a bone age (BA) of 14 yr in girls and 16 yr in boys, and LHRH-A (Lupron depot) was administered at a dose of 300 µg/kg·every 28 days in during 3 yr. We defined GH deficiency as patients with a growth velocity less than 4 cm/yr, BA delay more than 1 yr in relationship to chronological age, GH response to two stimulation tests less than 7 µg/L, associated with low serum insulin-like growth factor I and insulin-like growth factor binding protein 3 levels. Statistical analysis was performed by ANOVA or Kruskall Wallis when variances were not homogeneous. We observed a significant decrease in the rate of BA maturation in the group treated with GH+LHRH-A (1.5 ± 0.2 yr) compared with the group treated with GH alone (4.2 ± 0.5 yr) during the 3 years of LHRH-A therapy (P < 0.05). This delay in BA maturation produced a significant gain in final height in the group treated with GH+LHRH-A, which reached -1.3 ± 0.5 SD score compared with -2.7 ± 0.3 SD score (P < 0.05) in the group treated with GH alone. These results indicate that delaying puberty with LHRH-A in GHD children during treatment with GH increases final height.

This article has been cited by other articles:

				J.-C. Carel, E. A. Eugster, A. Rogol, L. Ghizzoni, M. R. Palmert, and on behalf of the members of the ESPE-LWPES GnRH An Consensus Statement on the Use of Gonadotropin-Releasing Hormone Analogs in Children Pediatrics, April 1, 2009; 123(4): e752 - e762. [Abstract] [Full Text] [PDF]

				N. Mauras, L. Gonzalez de Pijem, H. Y. Hsiang, P. Desrosiers, R. Rapaport, I. D. Schwartz, K. O. Klein, R. J. Singh, A. Miyamoto, and K. Bishop Anastrozole Increases Predicted Adult Height of Short Adolescent Males Treated with Growth Hormone: A Randomized, Placebo-Controlled, Multicenter Trial for One to Three Years J. Clin. Endocrinol. Metab., March 1, 2008; 93(3): 823 - 831. [Abstract] [Full Text] [PDF]

				M. J. E. Walenkamp, A. M. Pereira, W. Oostdijk, W. H. Stokvis-Brantsma, R. W. Pfaeffle, O. Blankenstein, and J. M. Wit Height Gain with Combined Growth Hormone and Gonadotropin-Releasing Hormone Analog Therapy in Two Pubertal Siblings with a Growth Hormone-Releasing Hormone Receptor Mutation J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 204 - 207. [Abstract] [Full Text] [PDF]

				C. Z. Michaylira, N. M. Ramocki, J. G. Simmons, C. K. Tanner, K. K. McNaughton, J. T. Woosley, C. J. Greenhalgh, and P. K. Lund Haplotype Insufficiency for Suppressor of Cytokine Signaling-2 Enhances Intestinal Growth and Promotes Polyp Formation in Growth Hormone-Transgenic Mice Endocrinology, April 1, 2006; 147(4): 1632 - 1641. [Abstract] [Full Text] [PDF]

				N. C. Kreher, E. A. Eugster, and R. R. Shankar The Use of Tamoxifen to Improve Height Potential in Short Pubertal Boys Pediatrics, December 1, 2005; 116(6): 1513 - 1515. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, A. D. Rogol, J. C. Lovejoy, M. Sheffield-Moore, N. Mauras, and C. Y. Bowers Endocrine Control of Body Composition in Infancy, Childhood, and Puberty Endocr. Rev., February 1, 2005; 26(1): 114 - 146. [Abstract] [Full Text] [PDF]

				S. E. Lerner, G. J. M. Huang, D. McMahon, C. A. Sklar, and S. E. Oberfield Growth Hormone Therapy in Children after Cranial/Craniospinal Radiation Therapy: Sexually Dimorphic Outcomes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6100 - 6104. [Abstract] [Full Text] [PDF]

				C. M. Brownstein, A. C. Mertens, P. A. Mitby, M. Stovall, J. Qin, G. Heller, L. L. Robison, and C. A. Sklar Factors That Affect Final Height and Change in Height Standard Deviation Scores in Survivors of Childhood Cancer Treated with Growth Hormone: A Report from the Childhood Cancer Survivor Study J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4422 - 4427. [Abstract] [Full Text] [PDF]

				J. A. Yanovski, S. R. Rose, G. Municchi, O. H. Pescovitz, S. C. Hill, F. G. Cassorla, and G. B. Cutler Jr. Treatment with a Luteinizing Hormone-Releasing Hormone Agonist in Adolescents with Short Stature N. Engl. J. Med., March 6, 2003; 348(10): 908 - 917. [Abstract] [Full Text] [PDF]

				M. Tauber, B. Berro, V. Delagnes, N. Lounis, B. Jouret, C. Pienkowski, I. Oliver, and P. Rochiccioli Can Some Growth Hormone (GH)-Deficient Children Benefit from Combined Therapy with Gonadotropin-Releasing Hormone Analogs and GH? Results of a Retrospective Study J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1179 - 1183. [Abstract] [Full Text] [PDF]

				V. Mericq, H. Gajardo, M. Eggers, A. Avila, and F. Cassorla Effects of Treatment with GH Alone or in Combination with LHRH Analog on Bone Mineral Density in Pubertal GH-Deficient Patients J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 84 - 89. [Abstract] [Full Text] [PDF]

				D. Mul, J .M. Wit, W. Oostdijk, and J. Van den Broeck The Effect of Pubertal Delay by GnRH Agonist in GH-Deficient Children on Final Height J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4655 - 4656. [Full Text] [PDF]

				W. M. Drake, S. J. Howell, J. P. Monson, and S. M. Shalet Optimizing GH Therapy in Adults and Children Endocr. Rev., August 1, 2001; 22(4): 425 - 450. [Abstract] [Full Text] [PDF]

				G. A. Kamp, D. Mul, J. J. J. Waelkens, M. Jansen, H. A. Delemarre-van de Waal, L. Verhoeven-Wind, M. Frolich, W. Oostdijk, and J. M. Wit A Randomized Controlled Trial of Three Years Growth Hormone and Gonadotropin-Releasing Hormone Agonist Treatment in Children with Idiopathic Short Stature and Intrauterine Growth Retardation J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 2969 - 2975. [Abstract] [Full Text] [PDF]

				G. Saggese, G. Federico, S. Barsanti, and L. Fiore The Effect of Administering Gonadotropin-Releasing Hormone Agonist with Recombinant-Human Growth Hormone (GH) on the Final Height of Girls with Isolated GH Deficiency: Results from a Controlled Study J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 1900 - 1904. [Abstract] [Full Text]